Modulation/NN
of/IN
the/DT
immune/JJ
response/NN
and/CC
tumor/NN
growth/NN
by/IN
activated/VBN
Ras/NN
./.

As/IN
a/DT
result/NN
of/IN
its/PRP$
transforming/VBG
abilities/NNS
,/,
activated/VBN
Ras/NN
is/VBZ
expressed/VBN
in/IN
a/DT
great/JJ
number/NN
of/IN
cancers/NNS
./.
=====
The/DT
ras/NN
mutation/NN
frequency/NN
varies/VBZ
between/IN
95/CD
%/NN
in/IN
pancreatic/JJ
cancer/NN
and/CC
5/CD
%/NN
in/IN
breast/NN
cancer/NN
./.
=====
In/IN
leukemia/NN
,/,
the/DT
highest/JJS
frequency/NN
(/(
30/CD
%/NN
)/)
is/VBZ
found/VBN
in/IN
acute/JJ
myeloid/JJ
leukemia/NN
./.
=====
The/DT
presence/NN
of/IN
ras/NN
mutations/NNS
has/VBZ
been/VBN
correlated/VBN
with/IN
a/DT
poor/JJ
prognosis/NN
and/CC
negative/JJ
clinical/JJ
outcome/NN
./.
=====
This/DT
suggests/VBZ
that/IN
mutated/VBN
Ras/NN
activates/VBZ
mechanisms/NNS
,/,
which/WDT
favor/VBP
tumor/NN
growth/NN
,/,
enhance/VBP
the/DT
metastatic/JJ
capacity/NN
of/IN
tumors/NNS
or/CC
modulate/VBP
tumor-specific/JJ
immune/JJ
responses/NNS
./.
=====
Several/JJ
new/JJ
functions/NNS
of/IN
Ras/NN
,/,
such/JJ
as/IN
downregulation/NN
of/IN
major/JJ
histocompatibility/NN
complex/NN
molecules/NNS
,/,
upregulation/NN
of/IN
certain/JJ
cytokines/NNS
,/,
growth/NN
factors/NNS
and/CC
degradative/JJ
enzymes/NNS
have/VBP
been/VBN
uncovered/JJ
in/IN
the/DT
last/JJ
decade/NN
./.
=====
Additionally/RB
,/,
mutated/VBN
Ras/NN
can/MD
also/RB
serve/VB
as/IN
a/DT
primary/JJ
target/NN
for/IN
the/DT
development/NN
of/IN
immunotherapy/NN
or/CC
drug/NN
therapy/NN
./.
=====
This/DT
review/NN
will/MD
discuss/VB
the/DT
mechanisms/NNS
by/IN
which/WDT
Ras/NN
expressing/NN
tumors/NNS
are/VBP
able/JJ
to/TO
evade/VB
destruction/NN
by/IN
the/DT
immune/JJ
system/NN
and/CC
enhance/VBP
their/PRP$
growth/NN
and/CC
metastatic/JJ
potential/NN
./.
=====
It/PRP
will/MD
further/RB
elaborate/VB
on/IN
the/DT
attempts/NNS
to/TO
develop/VB
successful/JJ
immunotherapy/NN
and/CC
drug/NN
therapy/NN
targeting/VBG
Ras/NN
expressing/NN
tumors/NNS
./.